Company / Net Debt per Share
Myriad Genetics, Inc. Net Debt per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Debt per Share
-$0.37
FY2025
5-year range
-$3.65 / -$0.37
FY2021-FY2025
Trend
+53.4%
vs FY2024
Sector context
#55 of 82
Health Care
What the data says
At $-0.37, Myriad Genetics, Inc.'s net debt per share ranks #28 of 82 in the Health Care sector. Net Debt per Share has fluctuated over the past 9 years, ranging from $-3.65 in FY2021 to $2.03 in FY2019.
Based on SEC 10-K filings.
-0.37 in FY2025.
Increased from $-1.24 to $-0.37 over the past 2 years.
Health Care sector context is included.
Net Debt per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#28 of 82 in Health CareTop 33% of 82This company -$0.37 Sector average $1.13
▼
-132.4% below sector average
Key checks
Key Insights
- In FY2025, net debt per share increased 53.4% year-over-year.
- Ranks #55 out of 82 companies in the Health Care sector.
- Peak net debt per share was recorded in FY2019.
- Lowest net debt per share in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.37 | +53.4% |
| FY2024 | -$0.79 | +36.8% |
| FY2023 | -$1.24 | -60.4% |
| FY2022 | -$0.77 | +78.8% |
| FY2021 | -$3.65 | -508.1% |
| FY2020 | $0.89 | -56.0% |
| FY2019 | $2.03 | +237.7% |
| FY2018 | -$1.47 | -3184.3% |
| FY2017 | -$0.04 | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026